

File downloaded on 2026-01-30

Source URL: <https://medicines.health.europa.eu/veterinary/en/600000078475>

PROGRAM Plus

Not authorised

- Milbemycin oxime
- Lufenuron

Product identification

Medicine name:

PROGRAM Plus

INTERCEPTOR PLUS compresse rivestite da 11,5 mg/230 mg per cani

Active substance:

Milbemycin oxime

Lufenuron

Target species:

Dog

Route of administration:

Oral use

Product details

Active substance and strength:

Milbemycin oxime

11.50 milligram(s) / 1.00 Tablet

Lufenuron

230.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:

Film-coated tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QP54AB51

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Surrendered

Authorised in:

Italy

Package description:

Carton container containing 8 pentagonal tablets in PVDC/PVC blisters, thermosealed with aluminium foil, boxed in a free-opening, labelled carton

Carton container containing 6 pentagonal tablets in PVDC/PVC blister, thermosealed with aluminium foil, boxed in a free-opening, labelled carton

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Elanco GmbH

Marketing authorisation date:

30/04/1998

Manufacturing sites for batch release:

Elanco France S.A.S.

Responsible authority:

Ministry Of Health

Authorisation number:

102569

Date of authorisation status change:

20/01/2025

Reference member state:

Italy

Procedure number:

IT/V/0106/003

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.